3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase NA
1
Phase 1
1
Status
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
pembrolizumab
512
Specimen Handling
381
Carboplatin
371
Magnetic Resonance Spectroscopy
333
Cisplatin
327
Nivolumab
302
Cyclophosphamide
295
Radiotherapy
254
Paclitaxel
252
Biopsy
235
Gemcitabine
229
Bevacizumab
212
Dexamethasone
167
durvalumab
162
Oxaliplatin
160
Capecitabine
154
Rituximab
151
Fluorouracil
148
venetoclax
142
atezolizumab
141
Docetaxel
141
Drug Therapy
140
Etoposide
138
Doxorubicin
131
Ipilimumab
125
Radiosurgery
118
Lenalidomide
117
Prednisone
116
Leucovorin
111
fludarabine
109
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Alemtuzumab
×
1 year
×
Clear all
NCT06084780
2026-06-05
TRANSCAPE
Case Comprehensive Cancer Center
Phase 2
Not yet recruiting
20 enrolled
NCT03821610
2026-05-05
ALL-RIC
University of Birmingham
Phase 2
Active not recruiting
242 enrolled